Markets:

Overview

News

Currencies

International

Treasuries

Cybin Inc. Common Shares (NY:CYBN)

5.980 -0.190 (-3.08%)

Streaming Delayed Price Updated: 10:25 AM EST, Nov 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cybin Inc. Common Shares

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

41 42 Next >

Cybin (NYSE American: CYBN) (NEO: CYBN) To Present At KCSA Psychedelics Conference ↗

April 22, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at KCSA Psychedelics Virtual Investor Conference

April 22, 2022

Via Investor Brand Network

Cybin to Participate in the KCSA Psychedelics Virtual Investor Conference on April 28, 2022

April 22, 2022

From Cybin Inc.

Via Business Wire

Revive Therapeutics, Field Trip Health Among Top Psychedelic Movers Of Today ↗

April 21, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 20.83% at $0.29

Via Benzinga

Volume of Gray Matter May Be Useful in Treatment Planning for Mental Health Conditions

April 21, 2022

Via Investor Brand Network

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Work with Clinilabs on Phase 1/2a Trial Focused on CYB003 for MDD Treatment

April 21, 2022

Via Investor Brand Network

Roth Capital Reveals Top Psychedelic Picks in New Industry Report

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Investment banks are continuing to release positive coverage for psychedelic stocks and the latest report...

Via FinancialNewsMedia

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder

April 21, 2022

From Cybin Inc.

Via Business Wire

Psychedelic Stock Gainers And Losers From April 20, 2022 ↗

April 20, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.69% at $0.16 LOSERS:

Via Benzinga

EXCLUSIVE: Catalysts To Watch For In The Psychedelic Space ↗

April 19, 2022

Any biotech investor knows how important catalysts are for the companies in the space. One FDA approval or denial can make or break the price of the stock. In the psychedelic space, catalysts could be...

Via Benzinga

Revive Therapeutics, Allied Among Top Psychedelic Movers Of Today ↗

April 19, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.57% at $0.33

Via Benzinga

EXCLUSIVE: How Cybin Is Developing The Next Generation Of Psychedelics ↗

April 19, 2022

If you’re just now considering the therapeutic value of psychedelics, Cybin Inc (NYSE: CYBN) is many trips ahead of you.

Via Benzinga

Cybin (NEO: CYBN) (NYSE American: CYBN) Pipeline Program Receives Key Patent Approval

April 19, 2022

Via Investor Brand Network

Topics Intellectual Property

Psychedelic Stock Gainers And Losers From April 18, 2022 ↗

April 18, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.66% at $0.28

Via Benzinga

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release ↗

April 18, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Cybin (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release

April 18, 2022

Via Investor Brand Network

Psychedelic Stock Gainers And Losers From April 14, 2022 ↗

April 14, 2022

GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 2.50% at $5.32

Via Benzinga

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Featured in Latest Power Play Release

April 14, 2022

Via Investor Brand Network

Psychedelic Stock Gainers And Losers From April 13, 2022 ↗

April 13, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 19.41% at $0.24

Via Benzinga

Cybin's (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study ↗

April 13, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

Cybin’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Advantages in Study

April 13, 2022

Via Investor Brand Network

PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB004 Demonstrates Significant Advantages over IV and Inhaled DMT in Pharmacokinetic Study

April 13, 2022

Via Investor Brand Network

Cybin's CYB0004 Shows Positive Preclinical Results Over Traditional Psychedelics ↗

April 13, 2022

CYB004 is one of Cybin’s (NYSE: CYBN) proprietary second-generation psychedelics, developed to treat depression, anxiety, and ...

Via Benzinga

Why Psychedelics Could Soon Replace Antidepressants

April 13, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 13, 2022 – Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults...

Via FinancialNewsMedia

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT

April 13, 2022

From Cybin Inc.

Via Business Wire

Psychedelic Stock Gainers And Losers From April 11, 2022 ↗

April 11, 2022

GAINERS: Small Pharma (OTC:DMTTF) shares closed up 4.52% at $0.17

Via Benzinga

Performance Comparisons Of The 5 Cannabis Sector Categories ↗

April 10, 2022

Here is a summary of how each of the 5 categories in the cannabis sector performed over four time periods, to highlight the different category trends that are underway.

Via Talk Markets

Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today ↗

April 08, 2022

GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 14.54% at $0.16

Via Benzinga

WIPO Publishes Cybin's Patent Application For Inhaled Psychedelics Therapies ↗

April 08, 2022

Cybin Inc. (NYSE: CYBN) announced that the World Intellectual Property Organization (WIPO) published an international patent ...

Via Benzinga

Cybin (NYSE American: CYBN) (NEO: CYBN) Strengthens IP Position Of Psychedelic Programs ↗

April 08, 2022

This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.

Via Benzinga

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.